Target molecules in specific immunotherapy against prostate cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Advances in molecular biology and tumor immunology enable identification of cancer antigens recognized by cytotoxic T lymphocytes (CTLs).
• Prostate cancer is a promising target for specific immunotherapy, with several tissue-specific antigens identified.
• Prostate-specific antigen (PSA) serves as a clinical course indicator, and other epithelial cancer antigens are relevant.

Purpose of the Study:

• To review prostate cancer-related antigens and their epitope peptides for immunotherapy.
• To introduce the current status of clinical trials for specific immunotherapy targeting these prostate cancer molecules.

Main Methods:

• Identification of genes encoding human cancer-related antigens and their peptides.
• Analysis of prostate tissue-specific antigens and their distribution.
• Review of identified epitope peptides and clinical trial data.

Main Results:

• Prostate cancer antigens are more localized than melanoma antigens, making them ideal for targeted immunotherapy.
• Numerous epitope peptides capable of generating prostate cancer-reactive CTLs have been identified.
• Clinical trials targeting these prostate cancer antigens and peptides are underway.

Conclusions:

• Prostate cancer is a strong candidate for specific immunotherapy among epithelial cancers.
• Identified prostate cancer antigens and peptides hold significant potential for patient immunotherapy.
• Ongoing clinical trials are evaluating the efficacy of targeted immunotherapies for prostate cancer.